{"doi":"10.15557/cgo.2019.0020","title":"A new prognostic index in patients with hormone receptor-positive and HER2-negative breast cancer","abstract":null,"journal":"Current Gynecologic Oncology","year":2019,"id":605503,"datarank":0.10397207708399181,"base_score":0.6931471805599453,"endowment":0.6931471805599453,"self_citation_contribution":0.10397207708399181,"citation_network_contribution":0.0,"self_endowment_contribution":0.10397207708399181,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":1,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1554011,"name":"Hayriye Şahinli","orcid":"0000-0002-1561-9346","position":1,"is_corresponding":false},{"id":1554013,"name":"Esra Zeynelgil","orcid":null,"position":2,"is_corresponding":false},{"id":1554014,"name":"Sema Türker","orcid":null,"position":4,"is_corresponding":false},{"id":1554015,"name":"Doğan Yazılıtaş","orcid":null,"position":6,"is_corresponding":false},{"id":1554016,"name":"Özlem Aydın İshak","orcid":null,"position":8,"is_corresponding":false},{"id":1554017,"name":"Mustafa Altınbaş","orcid":null,"position":10,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"A new prognostic index in patients with hormone receptor-positive and HER2-negative breast cancer","abstract":"Aim: Breast cancer is a heterogeneous disease. This study investigated the pretreatment prognostic significance of a new inflammatory index in hormone receptor positive (HR+) and human epidermal growth factor negative (HER2-) breast cancer patients. Methods: We retrospectively analyzed 80 patients diagnosed with HR+ and HER2-breast cancer between January 2014 and December 2018. We calculated prognostic inflammatory index (PII) = mean platelet volume (MPV) neutrophil/lymphocyte. PII cut off was the best-predicted value by receiver operating characteristic (ROC) curve analysis. We used the Kaplan-Meier method to determine disease-free survival (DFS). We used the log-rank test to compare the DFS rates between the two patient groups. We performed a multivariate analysis by performing Cox regression analysis with prognostic factors defined in univariate analysis. Results: The median follow-up period was 38 (19-66) months. The 5-year survival was 91.3%. The 5-year DFS was 87.9%. The optimal cut-off value of MPV neutrophil/lymphocyte ratio was determined as 22 by ROC curve analysis [area under the curve, AUC 735, HR % CI (confidence interval) 0.561-0.909, sensitivity 72.7%, specificity 70.4%]. The number of patients with PII 22 was 60, and the number of patients with PII >22 was 32. DFS was worse in the high PII group than in the low PII group (p = 0.001). Multivariate analysis revealed PII as an independent prognostic factor (p = 0.016). Discussion: In this study, we detected elevated MPV neutrophil/lymphocyte ratio as an independent poor prognostic factor in operated HR+ and HER2-breast cancer patients. Prospective studies are needed to determine the prognostic significance of this index.","is_dataset_classified":null,"base_score":0.6931471805599453,"endowment":0.6931471805599453,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"21097893","pmcid":null,"openalex_id":"https://openalex.org/W3017463824","authors":[],"funders":[],"total_grants":0,"fwci":0.0762,"citation_percentile":0.4382133,"influential_citations":0,"citation_trend":[{"year":2019,"count":1}],"oa_status":"bronze","license":null,"oa_locations":[{"url":"http://ginekologia.com.pl/artykul.php?a=830&key=dfdf3dee7ced40bb63aa27fd90d5ce27","host_type":"journal"},{"url":"http://ginekologia.com.pl/artykul.php?a=830&key=dfdf3dee7ced40bb63aa27fd90d5ce27","host_type":"publisher"},{"url":"http://ginekologia.pl/artykul.php?a=830","host_type":"publisher"},{"url":"https://doi.org/10.15557/cgo.2019.0020","host_type":"journal"}],"fields_of_study":["Breast Cancer Treatment Studies","HER2/EGFR in Cancer Research","Estrogen and related hormone effects"],"mesh_terms":[],"keywords":["Medicine","Hormone receptor","Oncology","HER2 negative","Breast cancer","Internal medicine","Cancer","Gynecology","Metastatic breast cancer"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-30T02:36:01.976121Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}